Cervical cancer
Conditions
Interventions
dose dense TC therapy (Carboplatin AUC =6 Day1 + Paclitaxel 80mg/m2 Day1, 8, 15) 3 weeks interval 3 cycles before surgery
Sponsors
Hyogo Cancer Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed cervical cancer. 2. FIGO stage Ib2, IIa2, IIb 3. ECOG PS =0 to 2 4. Patients with adequate function of principal organs. 5. Patients expected to live more than 3 months. 6. Patients older than 20 years. 7. Patients with informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with previous radiation therapy. 2. Any active double cancers. 3. Patients with any serious complications. 4. Patients with hypersensitivity to castor ail. 5. Patients with hypersensitivity to alcohol. 6. Carrier of HBV or HCV. 7. Patients with active infection which needs antibiotics. 8. Patients with interstitial pneumonia. 9. Pregnant woman. 10. Patients regard to be inadequate for entering this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year progression free survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate Pathological complete response rate 2-year overall survival Toxicity Site of recurrence Completion rate of neoadjuvant chemotherapy Pathological mapping of residual tumor Imaging findings of residual tumor | — |
Countries
Japan
Contacts
Public ContactKazuhiro Suzuki
Hyogo Cancer Center Gynecologic Oncology
Outcome results
None listed